Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Saturday, March 21, 2009

Developing Therapeutics for the Treatment of Multiple Sclerosis

doi:10.1602/neurorx.2.4.638
Copyright © 2005 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier Inc. - Science Direct


David J. Virley Ph.D.Corresponding Author Contact Information, a, E-mail The Corresponding Author

aNeurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Harlow, Essex CM19 5AW, United Kingdom


Available online 3 March 2006.

Summary

Multiple sclerosis (MS) is both a complex and chronic neurological disease of the CNS. This poses unique challenges for drug discovery in terms of delineating specific targets related to disease mechanisms and developing safe and effective molecules for clinical application. Preclinical animal models of MS provide the necessary test bed for evaluating the effects of novel therapeutic strategies. Because the clinical manifestations and pathological consequences of disease vary dramatically from individual to individual, as well as treatment response to existing therapies, this creates a significant research endeavor in terms of translating preclinical methodologies to the clinical domain. Potentially exciting treatments have emerged in the form of natalizumab (Tysabri), an α4 integrin antagonist, and more recently FTY720, a sphinogosine-1 phosphate receptor modulator, providing a compelling proof-of-principle from bench to bedside. However, further research is required to discharge safety concerns associated with these therapeutic avenues. Future prospects in the guise of disease-modifying therapies that target the inflammatory and neurodegenerative components of disease have come to the forefront of preclinical research with the sole aim of reducing the underlying irreversible progressive disability of MS. Significant progress with novel therapies will be made by implementing biomarker strategies that extrapolate robustly from animal models to the divergent patient populations of MS. The future therapeutic options for MS will depend on improvements in understanding the precise factors involved in disease onset and progression and subsequently the development of oral therapeutics that translate sustained benefit from the preclinical context into clinical reality.

Key Words: Multiple sclerosis; inflammation; demyelination; regeneration; experimental autoimmune encephalomyelitis; therapeutics

Article Outline

INTRODUCTION
EVALUATION OF CLINICAL OUTCOME IN MS
ANIMAL MODELS OF MS
CURRENT THERAPIES FOR MS
Corticosteroids
IFN-β
GA
EXAMPLES OF NOVEL THERAPEUTIC CHALLENGES FOR MS
Blockade of lymphocyte migration
Very late antigen-4: natalizumab (Tysabri) and small molecule antagonists.
Immunomodulatory agents
FTY720: sphinogosine-1 phosphate modulator.
Anti-inflammatory agents
COX-2 inhibitors.
Neuroprotective and neuroregenerative therapeutic strategies
Potential combinations of therapeutic strategies
FUTURE GOALS FOR DRUG DEVELOPMENT: TRANSLATIONAL SIGNIFICANCE
CONCLUSION
Acknowledgements
References


Corresponding Author Contact InformationAddress correspondence and reprint requests to David J. Virley, Ph.D., Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom.


.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

MS Patients Suffer As A Result Of Insurance Pricing Scheme

.
Medical News Today

Patients Suffer As A Result Of Insurance Pricing Scheme
21 Mar 2009

Millions of patients suffering from diseases such as rheumatoid arthritis, multiple sclerosis, hemophilia, hepatitis C and certain types of cancer are at risk of incurring thousands of dollars in medical expenses due to a new pricing system being implemented by many insurance companies across the United States.

Health insurance companies are rapidly adopting this new system, commonly called Tier IV, for many of the expensive drugs used in the treatment of several diseases asking patients to pay hundreds and even thousands of dollars a month for needed prescriptions. Blue Cross Blue Shield of Mississippi was one of many insurance companies to adopt this system, forcing its policyholders to shoulder 20 to 40 percent of the costs of their medication.

» Read More

Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

Friday, March 20, 2009

MS Related - New drug protects nerve cells from damage in mice

Multiple sclerosis (MS) is a chronic inflammatory disease of the brain and spinal cord. Individuals with MS develop progressive neurological disability, and this is thought to be caused by degradation of the nerve cells.

It is therefore hoped that treatments that protect nerve cells might help individuals with the progressive form of MS. Data to support this hypothesis has now been generated using a chronic progressive EAE mouse model of MS by Howard Weiner and colleagues at the Brigham and Women’s Hospital, Harvard Medical School, Boston.

In the study, treatment of mice after the onset of disease with a water-soluble agent known as ABS-75, which has antioxidant properties and blocks the stimulation of the subset of nerve cells that express the NMDA receptor, markedly reduced disease progression.

This beneficial effect was associated with decreased nerve cell degradation, and a similar protective effect was observed for ABS-75 when it was added to cultured nerve cells exposed to damaging reagents. These data led the authors to suggest that agents similar to ABS-75 might provide a new approach to treating individuals with MS and other neurodegenerative disorders.

Source: Journal of Clinical Investigation --March 14th

Printed source: Phys.org.

Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

MS Action Alert- Help Secure $15 Million for MS Research

Last year, MS activists reached a new milestone and helped secure $5 million for MS research in FY 2009 under the Congressionally Directed Medical Research Programs (CDMRP). The CDMRP is a Department of Defense (DoD) program that is funded annual via the Defense Appropriations Act.

Let's take the next step together and help secure more funding for MS research under the CDMRP. Ask your members of Congress to support a $15 million appropriation under the CDMRP that will help scientists to better understand the causes of MS and help find a cure. The large number of grant proposals recently submitted to the DoD for MS projects indicate that there is a clear need for more funding for MS research.

Take Action Now!
  • Call your legislators' Washington, D.C. office to talk about this issue. Call the Capitol switchboard at 1-800-828-0498 to be connected.
  • Click here to follow up with a quick e-mail to your Senators and Representative.
Now is the perfect time to reinforce the message that MS activists took to Capitol Hill during the Public Policy Conference last week.




.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

Wednesday, March 18, 2009

Apitope announces licensing agreement for ATX-MS-1467

Apitope, a Bristol University spinout company that is looking at a potential therapy for people with Multiple Sclerosis (MS), has announced a licensing agreement for up to 154 million in upfront, development and commercialisation milestone payments, in addition to royalties, to develop its peptide therapeutic for the treatment of MS.

Apitope founded by Professor David Wraith in the University Department of Cellular and Molecular Medicine, has granted exclusive worldwide rights to Merck Serono to develop and commercialise Apitope peptide therapeutic product, ATX-MS-1467. Apitope is eligible to receive up to 154 million in upfront, development and commercialisation milestone payments, in addition to royalties on the net sales of products resulting from the collaboration.

» Read More


============================================

Heat Intolerance Affects many with Multiple Sclerosis

An Overview of Heat Intolerance

By Julie Stachowiak, Ph.D., About.com - Originally Published June 26, 2008
About.com Health's Disease and Condition content is reviewed by the Medical Review Board

For many of us with multiple sclerosis (MS), summer fills us with anxiety. Hot weather means MS symptoms and, well, suffering. As most people are going outside to enjoy the hot weather, we are drawing the blinds and resigning ourselves to cleaning out closets and reading novels. Even vacations are a challenge, as each year we look for places further from the equator or “adventures” that take place in air-conditioned coolness.

Heat intolerance in MS shows up as a "pseudoexacerbation" -- the experience of having symptoms appear or worsen due to heat exposure. This is different than a true relapse. In the case of a pseudoexacerbation, when the body’s temperature returns to normal, these symptoms disappear. No damage, such as inflammation, demyelination or new lesions, has been done during these pseudoexacerbations.

» Read More

Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

MS Related: Dendritic Cells Ensure Immune Tolerance

Science Daily

ScienceDaily (Mar. 16, 2009) — One of the most important tasks of the immune system is to identify what is foreign and what is self. If this distinction fails, then the body's own structures will be attacked, the result of which could be an autoimmune disease such as diabetes mellitus type 1 or multiple sclerosis. The only way to protect against these afflictions is to destroy all immune factors that turn against the body’s own tissue – in other words: immune tolerance.

A team working with LMU researcher Dr. David Vöhringer has now investigated exactly what role dendritic cells play in this process. There has long been suspicion that these cells, which are important for the body’s defenses, are also essential for the establishment and maintenance of immune tolerance. “We investigated mice that lacked this cell type from birth,” reports Vöhringer. “It turned out that immune cells that attack the body’s own tissue survive in these animals, and thereby trigger an autoimmune response. It follows that dendritic cells play a major part in protecting against autoimmune disease.”

» Read More

Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

MS news from Australia - Former union boss makes MS battle public

Australian Broadcasting Corporation

Broadcast: 17/03/2009 -- Reporter: Sharon O'Neill

Former Maritime Union boss John Coombs made his family’s private battle public when he went to Canberra this week to help put the case for increased federal government funding for Multiple Sclerosis research. John Coombs and his wife Gwen are the full time carers of their son Garry, who was diagnosed with MS nearly twenty years ago.

Transcript:

KERRY O'BRIEN, PRESENTER: Here is a story about a very personal and inspirational battle: multiple sclerosis, which afflicts 20,000 people in Australia, some of them for decades.

When John Coombs retired as head of the Maritime Union, it was assumed his biggest battles were behind him. But his retirement has been his toughest. John Coombs and his wife Gwen are the full-time carers of their son Gary, who has multiple sclerosis. Today, the former wharfies boss made his private struggle public when he went to Canberra to help put the case for increased Federal Government funding for MS research. Sharon O'Neill reports.

Be redirected to the ABC.net.au website to continue reading this story.

Return here to leave a comment. - Thank You

Montel Williams Speaks out of his battles with Multiple Sclerosis

Overcoming Pain and Depression

Montel's interview appeared on Oprah Winfrey on March 17, 2009 -
Below you can read this interview..

Every hour, someone in the world is diagnosed with multiple sclerosis (MS), a life-threatening neurological disease. Ten years ago, Emmy-winning talk show host Montel Williams was one of these people.

At first, this former Naval intelligence officer chose to hide his pain, but when a tabloid newspaper threatened to print his story, he decided to go public with his health crisis. Montel spoke about his diagnosis on his talk show, but few people knew how much he was suffering.

On set, Montel conducted interviews with poise. Then, during commercial breaks, he says he'd go backstage, sit down and cry because of the pain. "[I would] let it go, refocus, come back out and sit down, and do another interview with a person," he says. "I was doing that every day."

Continue reading by clicking here, which will re-direct you to the Oprah.com website

Then, please return here to leave any comments you may have. Thank You
============================================

Tuesday, March 17, 2009

MS Research News: demyelination and remyelination / Grey matter / Neutralizing antibodies in multiple sclerosis

Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels

It is known that the damage which occurs in the axons (specific parts of the neurons in charge of the conduction of electrical signal) is, at least partly, responsible for the development of disability in MS. It is also known that acute inflammation is involved in causing axonal damage. The authors of this study have validated the usefulness of a specific MRI technique (MTR) in monitoring the processes of damage (demyelination) and recovery (remyelination) which take place when an acute MS lesion appears, considering that the better the recovery the lower the probability of axonal damage.

authors: Giacomini PS, Levesque IR, Ribeiro L, Narayanan S, Francis SJ, Pike GB, Arnold DL

source: Arch Neurol. 2009 Mar;66(3):375-81

++++++++++++++++++++++++++++++++++++++++

Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis

In this study the authors aimed to investigate, in people with secondary progressive MS, the correlation of disability with damage seen in the normal appearing brain tissue by means of a new MRI technique (MTR) and the lesion burden measured by means of conventional (T2-wighted) MRI. They found that the damage in the grey matter showed the strongest correlation with clinical outcome. These results highlight the usefulness of the MTR as a technique which accurately reflects brain tissue changes in MS (even better than conventional MRI) and also emphasise the role of the grey matter in the development of disability.

authors: Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Hunter K, Tozer DJ, Miller DH, Kapoor R

source: J Neurol. 2009 Mar 6

++++++++++++++++++++++++++++++

Neutralizing antibodies in multiple sclerosis patients treated with 375 mug interferon-beta-1b

The IFN-beta represents one of the most widely used treatments in MS. Nevertheless, its efficacy might be diminished by the presence of neutralising antibodies (NAbs), which reflect an immune reaction against the treatment. In this multicentre study the authors looked at the harmful effects produced by NAbs on clinical and MRI outcomes produced by NAbs. They found that even though MRI parameters showed worse evolution in people with higher NAbs frequency, no effect of NAbs on clinical outcome was observed.

authors: Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M

source: Expert Opin Biol Ther. 2009 Mar 11

+++++++++++++++++++++++++++++++++++++
Source for the above articles : http://www.msif.org
+++++++++++++++++++++++++++++++++++++

If reading this and not yet subscribed to receive the Stu's Views and MS Related News, weekly MS e-Newsletter, then click here to register at the MS Views and News, Inc., website. - Thank you.

.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

High field MRI in the diagnosis of multiple sclerosis. High field-high yield?

source: msif.org for pubmed article -

summary: In this review the authors highlight the advantages of new high field MRI techniques in showing damaged regions in the brain that with conventional techniques (standard field strengths) cannot be visualised. This improvement in depicting changes in brain tissue may help us to better understand the underlying processes occurring in MS, which at the same time may have a number of practical applications.

Wattjes MP, Barkhof F.
MS Center Amsterdam, Department of Radiology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands, m.wattjes@vumc.nl.

Following the approval of the U.S. Food and Drug Administration (FDA), high field magnetic resonance imaging (MRI) has been increasingly incorporated into the clinical setting. Especially in the field of neuroimaging, the number of high field MRI applications has been increased dramatically.

» Read More

Want to leave a comment? Return to this page. Thank You
============================================

Pediatric optic neuritis: brain MRI abnormalities and risk of multiple sclerosis

The authors of this article aimed to investigate MRI factors involved in a higher risk of development of MS after an episode of optic neuritis in children. The risk of MS significantly increased in children with at least one lesion seen on a brain MRI performed during the episode of optic neuritis. Children with normal scans had a very low risk of developing MS.

authors: Bonhomme GR, Waldman AT, Balcer LJ, Daniels AB, Tennekoon GI, Forman S, Galetta SL, Liu GT

source: Neurology. 2009 Mar 10;72(10):881-5 - pubmed -

Bonhomme GR, Waldman AT, Balcer LJ, Daniels AB, Tennekoon GI, Forman S, Galetta SL, Liu GT.
Division of Neuro-Ophthalmology, Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.

BACKGROUND: Optic neuritis is often the initial presentation of multiple sclerosis (MS). As established by the Optic Neuritis Treatment Trial, an abnormal baseline brain MRI is a strong predictor of MS after isolated optic neuritis in adults. However, the rate of conversion to MS after optic neuritis in children based upon brain MRI findings is unknown.

» Read More

.
Please return here to leave a comment. Thank You
============================================

Efficacy of treatment of MS with IFN{beta}-1b or glatiramer acetate by monthly brain MRI in the BECOME study.

source: msif.org

From the Departments of Neurology and Neuroscience (D.C., J.L., J.C., K.S., S.S.K., A.R.P., S.D.C.), Radiology (L.J.W.), and Preventive Medicine and Community Health (J.S.) of UMDNJ-New Jersey Medical School, Newark; and the Multiple Sclerosis Center at Holy Name Hospital (D.C., S.S.K., J.H.), Teaneck, NJ.

In this randomized trial the efficacy of IFNb-1b (Betaferon/Betaseron®) and glatiramer acetate (GA, Copaxone®) were compared. Seventy-five people with RRMS were included in the study. After a 2-year treatment period the authors found no differences between the 2 groups in terms of MRI activity (new lesions and enhancing lesions) and clinical activity (new relapses).

» Read More

Please return here to post comments - Thank You
============================================

New edition of MS in focus on ataxia and tremor

March 2009
New edition of MS in focus on ataxia and tremor
Just published: Issue 13 of our biannual magazine looks in detail at the difficult MS symptoms of ataxia and tremor.
This latest edition of our magazine contains articles from leading ataxia and tremor experts from around the world, as well as answers to your questions on the subject and the results or the ataxia and tremor online survey.

Download the English language PDF
here or email info@msif.org for your free printed copy. German, Spanish and French editions will be available soon.

------------------------------

Montel Williams discusses his MS Diagnosis with Dr. Oz

Information provided by Marianne in NY


Dr. Oz: After the Diagnosis with Montel Williams
(OAD 03/17/2009)
For 10 years, Montel Williams has been in the fight of his life. After a devastating diagnosis…what do you do next? Dr. Oz reports.
Montel Williams talks about the fight for his life.
For years, Montel Williams has suffered from multiple sclerosis. The pain, depression and daily struggle…a candid discussion with Dr. Oz.

Dr. Oz spends a day with Montel Williams.
Dr. Oz visits Montel at home to see how diet, exercise and medication help him make it through the day. How he turns pain into something positive.

Montel Williams' book Living Well Emotionally
Why is it important to ask for help after a serious diagnosis? Find out in this excerpt from Montel's latest book.


Dr. Oz reveals what you should do after a serious diagnosis.
Dr. Oz reveals the five things you should do before—and after—getting a dreaded diagnosis from your doctor.

.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

For Entertaining BeWilderment (is this a word)...

Provided by Susan in Miami:

First click the link, then click on play, and then leave the mouse alone,
sit back and enjoy .......this is very creative

http://fc01.deviantart.com/fs13/f/2007/077/2/e/Animator_vs__Animation_by_alanbecker.swf


====================================

Monday, March 16, 2009

Studies to be considered for persons with Multiple Sclerosis

On the MS Views and News, Inc, website, there is information for those who might have the Pseudobulbar Affect... Uncontrollable laughing or crying.
Click the link to visit our homepage and then on the box which explains Pseudobulbar.
----------------------------
Also click the info ad for The BRAVO clinical study. A global clinical research study designed to explore the efficacy, safety and tolerability of an experimental drug, laquinimod. Laquinimod is currently being studied as a once-daily oral investigational drug for relapsing-remitting multiple sclerosis (RRMS).
----------------------------
For both shown above - visit our website to learn more of
both of these important studies.
http://www.msviewsandnews.org


THANK YOU
============================

"The Show Must Go On" - By Kristie Salerno

A Video prepared by Kristie Salerno, that you can use to demonstrate how
some of your symptoms feel.
Best to use for those that simply can't understand, what you might or might not be feeling.

Click here, then scroll down the homepage to view the video.
When you find the video for The Show Must Go on, click the arrow to begin watching.



============================================

View to see How Tysabri Works


Adhesion Molecule Inhibitors

Click link to see How Tysabri works:

http://www.youtube.com/watch?v=9zLYxr2Tv7I



.
Have a Question, Comment or information for others?
If so, please use the post comment link found below.
Your name and email address would be appreciated but is not necessary unless you want a response from others.
Thank You

============================================

Sunday, March 15, 2009

Attention Stu's Views and MS News, Blog Readers...

Dear Readers,

Good day.

Your help is being sought to bring others to this blog. But now only to this blog, but to also be registered to receive our weekly MS e-newsletter, that you enjoy receiving each week.

We want to grow, but cannot do this without your assistance.

For all whom you know affected by MS, please ask them to register at our website.

Remember please that being affected by Multiple Sclerosis does not stop with just the patient. Family, friends and medical providers are also affected. Anybody who associates with the MS patient IS affected.

And it's these people, in addition to others with MS whom we want to receive the information that is provide by this blog or our website and via the weekly "Stu's Views and MS Related News", e-Newsletter.

Via our website we offer links to most major globally known MS organizations.
Via this blog, there are links to many of these same organizations as well as to other MS Bloggers. MS Views and News, Inc strives to bridge the gaps in available MS information.

This is what you could send to others suggesting that they register. >> Click Here <<

The more who can learn, the better for all...

Thank You...

Stuart Schlossman




============================================